The Axial Spondyloarthritis (axSpA) refers to a chronic inflammatory disease that primarily affects the spine and sacroiliac joints. AxSpA encompasses both ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Common symptoms include chronic back pain, fatigue, stiffness and limited mobility of the spine. The disease is associated with chronic swelling at the sites of attachment between the spinal vertebrae and sacroiliac joints. If left untreated, this can eventually lead to fusion of the vertebrae and complete loss of spinal mobility. Biologics such as tumor necrosis factor (TNF) inhibitors are the standard treatment option for managing signs and symptoms as well as slowing progression of structural damage.
The axial spondyloarthritis (axSpA) treatment market is estimated to be valued at USD 6.02 billion in 2024 and is expected to reach USD 10 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.
Key Takeaways
Key players operating in the Axial Spondyloarthritis (axSpA) market are Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Novartis AG, UCB SA.
The prevalence of Axial Spondyloarthritis (axSpA) Treatment Market is rising globally owing to lifestyle changes, increasing environmental stressors and a better understanding of the disease. According to estimates, spondyloarthritis affects around 1-2% of the global population. Improved diagnosis tools and biomarker research is aiding in early detection and diagnosis of Axial SpA, thus driving the demand for treatment.
Get more insights on: Axial Spondyloarthritis (axSpA) Treatment Market